ARIC STUDY MANUSCRIPT PROPOSAL # 714. PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority:

Similar documents
ARIC Manuscript Proposal # 1518

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Mood, depression, and reproductive hormones in the menopausal transition

WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH

ARIC Manuscript Proposal #1491. PC Reviewed: 03/17/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

OVERVIEW OF MENOPAUSE

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

Therapeutic Cohort Results

prevalence was 13.8% among females

One Day Hormone Check

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

Physiology of Menopause

Hormone replacement therapy and breast density after surgical menopause

Therapeutic Cohort Results

One Day Hormone Check

Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes

Effects of Transdermal Estradiol in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial

Menopausal hormone therapy currently has no evidence-based role for

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare

Gary Elkins, PhD., ABPP

Therapeutic Cohort Results

Supplementary Online Content

Helpful information about bone health & osteoporosis Patient Resource

MENOPAUSAL SYMPTOMS ARE ASSOCIATED

Managing menopause in Primary Care and recent advances in HRT

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer

Reproductive Health Policy Brief

Chronic Pain and Opioid Use in Women Veterans: Is there an Association with Menopause?

Epidemiologic studies have clearly demonstrated that

Neuroendocrine Evaluation

Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women

Finding Our Reasons to Choose Estrogen PRE- HRT. Learning Objectives. Disclosure. Learning Objectives. Replacement Therapy. For Previvors 6/1/17

Glinda S. Cooper, 1 Donna D. Baird, 1 and F. Rebecca Darden 2

ORIGINAL ARTICLE. Depression and Its Influence on Reproductive Endocrine and Menstrual Cycle Markers Associated With Perimenopause

Australian Longitudinal Study on Women s Health

Long-Term Health Outcomes of Surgical Menopause

ARIC Manuscript Proposal #2426. PC Reviewed: 9/9/14 Status: A Priority: 2 SC Reviewed: Status: Priority:

BSO, HRT, and ERT. No relevant financial disclosures

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Orals,Transdermals, and Other Estrogens in the Perimenopause

Individual Study Table Referring to Part of the Dossier. Volume: Page:

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:

Vol-5 No-1 Jan-Mar 2012

Heart Disease in Women: Is it Really Different?

Higher levels of cognitive inflexibility relate to higher levels of symptom reporting at menopause

Controversies in Primary Care Pros and Cons of HRT on patients with CHD

Sex, hormones and the heart

Society for Behavioral Medicine 33 rd Annual Meeting New Orleans, LA

Menopause and HRT. John Smiddy and Alistair Ledsam

By Lora A. Connor B.A., 2008, California State University, Long Beach

Assessment and Treatment of Depression in Menopause

Managing menopause in Primary Care and recent advances in HRT

Female New Patient Package

ABSTRACT REPRODUCTIVE AND HORMONAL FACTORS IN RELATION TO LUNG CANCER AMONG NEPALI WOMEN

WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

Leslie R. Schover, PhD Department of Behavioral Science

Breast Cancer Risk Assessment and Prevention

Body mass index following natural menopause and hysterectomy with and without bilateral oophorectomy

This information can be found by going to Hot Flashes

Female Patient Questionnaire & History

Does Hysterectomy Lead to Weight Gain or Does Overweight Lead to Hysterectomy?

Does this project require contact of CCSS study subjects for...

Is Alcohol Use Related To High Cholesterol in Premenopausal Women Aged Years Old? Abstract

Numerous symptoms are commonly attributed to

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with

IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII

Hormone Treatments and the Risk of Breast Cancer

ANNALS of Internal Medicine

Menstrual Cycle as Focus of Study and Self- Reports of Moods and Behaviors

PMS / PMDD. Prof John Studd Imperial College London London PMS and Menopause Centre. www. studd.co.uk

Women s Mental Health

Female New Patient Package

Female Patient Questionnaire & History

CONSENSUS RECOMMENDATIONS Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations

BONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis

Andrew J. Dimond, David S. Krantz, Andrew J. Waters, Romano Endrighi, Stephen S. Gottlieb

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

Smoking Status and Body Mass Index in the United States:

ARIC Manuscript Proposal #2493. PC Reviewed: 2/10/15 Status: A Priority: 2 SC Reviewed: Status: Priority:

Arizona Natural Medicine, L.L.C W. Ray Road, Suite 1, Chandler, AZ

Flashpoint: Regulating Your Body s Temperature. Presented by: Shari M. Lawson, MD MBA Date Presented: November 1,

An Evidence-based Review of Clinical Trial Data

SBM Annual Meeting and Scientific Sessions Topic Area Descriptions

Sleep Apnea in Women: How Is It Different?

Menopausal vasomotor symptoms and incident breast cancer risk in the Study of Women's Health Across the Nation

Psychosocial Issues for People with Diabetes. Richard Arakaki, M.D. Phoenix Area Diabetes Consultant June 28, 2017

Heart Disease in Women. Charlotte A. Lee, M.D., DBIM, FLMI

The Female Brain: Balancing Social Expectations with Your Own Health 10/30/12. Louann Brizendine, MD

3 SAMPL E REPORT S. This Assessment features three reporting options: Rhythm Adrenocortex Stress Profile Comprehensive Melatonin Profile GDX-4-225

Psychologic Distress and Natural Menopause: A Multiethnic Community Study

Transcription:

1 ARIC STUDY MANUSCRIPT PROPOSAL # 714 PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority: 1. a. Full Title: Effect of menopausal status on mood: The influence of demographic and psychosocial characteristics b. Abbreviated Title (Length 26): Menopause and mood 2. Writing Group (list individual with lead responsibility first): Kelly J. Rohan, Patricia M. Dubbert, Cecil Burchfiel, Sharon Wyatt, Edward Meydrech, Gail Hughes Lead: Kelly J. Rohan, Ph.D. Mental Health Service (116B) Veterans Affairs Medical Center 1500 East Woodrow Wilson Drive Jackson, MS 39216 Phone: (601) 362-4471, ext. 1161 Email: Kelly.Rohan@med.va.gov 3. Timeline: Data analysis will begin following Publications Committee approval. We expect to begin manuscript preparation immediately and to submit the manuscript for publication within 9 months of proposal approval. 4. Rationale: Menopause-related changes in mood and well-being are important women s health issues. Some reviews have concluded that incidence of Major Depressive Episode among women across the life span are analogous to plasma levels of estrogen with peaks during childbearing and perimenopausal years 1. A few prospective studies have found elevated levels of clinical depression 2 and depressive symptoms 3 among perimenopausal women relative to menopausal and premenopausal women. Recently, several large-scale studies and national surveys have attempted to clarify any relations between menopausal status and affective symptoms. Analysis of the NHANES data revealed a significant relative risk of Major Depression during perimenopause and natural menopause based on Center for Epidemiological Studies Depression Scale- (CESD-) criteria, but these became nonsignificant after controlling for depression history 4. The Massachusetts Women s Study also found that perimenopause was associated with elevated rates of clinical depression defined by CES-D scores 5. Among women who were not clinically depressed at the initial assessment, those who went from premenopause to perimenopause or who remained perimenopausal had higher rates of depression 27 months later than those who remained premenopausal or postmenopausal. In the Healthy Women

2 Study, postmenopausal and premenopausal women did not differ on the Beck Depression Inventory scores, but perimenopausal women self-reported more depressive symptoms than premenopausal controls 6. Several studies have examined whether mood-menopause relations differ depending on type of menopause [i.e., occurring naturally, surgically induced, or including bilateral oophorectomy (BSO)]. Effects of initiation of hormone replacement therapy (HRT) on mood are also of interest. Results of the Healthy Women Study revealed no differences between hysterectomy, BSO and HRT, BSO only, and premenopausal women on self-reported depressed mood, psychosomatic symptoms, anxiety, or anger 7. The NHANES study found no differences in depressive symptoms, general well-being, or sleep between women who underwent surgical menopause with and without BSO 4. In a meta-analysis of 26 studies assessing the effects of HRT on menopausal depressed mood, estrogen only or in combination with androgen exerted moderate to large effects (reduced depressive symptoms) in pre-treatment to posttreatment and treatment to control comparisons 8. Thus, current findings suggest that some women may experience negative mood changes with onset of perimenopause. Differences across studies may reflect differences in methodology (e.g., how perimenopause is defined and which dependent measures are used). In addition, some factors appear to moderate the effects of menopausal status on mood, including history of clinical depression 4, exercise participation 9, duration of menopause 10, and initiation of HRT 8. Although reviews emphasize the importance of examining race and SES as moderating factors in menopausal experience 11, no reports using large-scale survey data have done so. Although race and SES could serve as markers for different educational and cultural influences on response to hormonal change, surprisingly, studies that sampled across race and SES (e.g., NHANES and the Massachusetts Women Study) have not examined these moderating variables in relation to menopausal mood changes. Because ARIC sampled African American and Caucasian women from various SES groups, sufficient power to conduct such analyses could be attained. Unlike other large surveys, the ARIC database contains other possible moderating variables such as physical activity level, social support, antidepressant medication use, smoking behavior, alcohol consumption, and various medical conditions. In addition, ARIC used unique psychosocial measures (i.e., vital exhaustion and anger), not previously assessed through the menopausal transition. The proposed study will examine the relation between menopausal status and psychosocial dimensions in a biethnic sample (i.e., African American and Caucasian). Women varying in hormonal status [premenopausal, perimenopausal, postmenopausal (natural or surgical; with or without BSO, with or without HRT)] will be included as participants. Several moderating variables will be considered: race, SES, HRT use, physical activity level, social support, antidepressant medication use, cigarette smoking, alcohol consumption, and presence of health conditions (DM, cancer, CHD, stroke). Research questions include: (1) Will the findings of increased negative affect at perimenopause be replicated in the ARIC data, which included novel mood and psychological measures? (2) Will any moderating variables of the mood-menopausal status relation emerge?

3 (3) Will type of menopause (surgical vs. natural) or initiation of HRT differentially impact mood across the menopausal transition? 5. Main Hypotheses: The primary hypothesis is that perimenopausal status will be related to higher self-reported vital exhaustion and trait anger. Low SES, physical inactivity, poor social support, no HRT, smoking, excessive alcohol consumption, and presence of medical conditions are expected to emerge as moderating factors, associated with greater depressive symptoms. 6. Data (variables, time window, source, inclusions/exclusions): The Vital Exhaustion Scale and State-Trait Anger Expression Inventory (from the Health and Life Profile) will be used as dependent measures. Menopausal status can be inferred from answers to questions regarding regularity of menstruation, and, in particular, changes in self-reported menstrual status between visits. Other variables of interest include ethnicity, income, age, hormone use, social support, physical activity, antidepressant medication use, smoking behavior, alcohol consumption, and prevalent health conditions. 7. Analyses: In defining menopausal status, we will use the menopause-derived variable developed and used by Nabulsi et al. (1993) 12 in their investigation of HRT and cardiovascular risk factors among postmenopausal ARIC participants. This variable is categorical: primary amenorrhea, premenopause, perimenopause, natural menopause (no menstruation during the past 2 years, including women who underwent hysterectomy, leaving one or two ovaries intact, and were age 55 or over), surgical menopause (no menstruation in the past 2 years and bilateral oophorectomy), and unknown ovarian status. Women classified as primary amenorrhea and unknown ovarian status will be excluded from our analyses. Whereas Nabulsi et al. (1993) used baseline ARIC data, we are interested in classifying women into menopausal status categories at Visits 2, 3, and 4 as well coding changes in menopausal status between these visits. Vital Exhaustion: Hypotheses regarding vital exhaustion (assessed at Visit 2 only) will be evaluated through cross-sectional analyses. Consistent with the approach of Nabulsi et al. (1993), we plan to conduct an analysis of covariance (ANCOVA) using vital exhaustion as the dependent variable and Visit 2 menopausal status as the independent variable, controlling for age. Several moderating variables will be included: race, SES (Visit 1 education and income), and physical activity (Visit 1 leisure, sports, and work-related). Other moderating variables concurrently assessed at Visit 2 include hormone use (estrogen, progestin, or combination), social support, tobacco use (cigarette, cigar, or pipe smoking), alcohol consumption, antidepressant medication use, and prevalent health conditions (DM status, cancer at any cite, and coronary heart disease).

Trait Anger: The above analysis will be repeated using Visit 2 trait anger as the dependent variable. However, because trait anger was assessed at Visits 2 and 4, a longitudinal statistical approach is also appropriate. Specifically, we plan to examine changes in trait anger as a function of change in menopausal status. With change in trait anger from Visit 2 to 4 as the dependent variable, we will conduct an ANCOVA using change in menopausal status from Visit 2 to 4 as the independent variable, controlling for age. Moderators will include race, SES, physical activity (Visit 3 leisure, sports, workrelated), and Visit 2 social support. Other possible moderating variables will be entered, including hormone use, tobacco use (cigarette, cigar, or pipe smoking), alcohol consumption, antidepressant medication use, and prevalent health conditions (DM, cancer, CHD, and stroke). Given that the ARIC cohort was 45 to 64 years old at Visit 1, it is unlikely that many women will remain premenopausal across all visits. Thus, data for any women classified as premenopausal at Visit 4 will be excluded from this longitudinal analysis. 4

5 References 1. Stahl, S. M. (1998). Basic psychopharmacology of antidepressants, part 2: Estrogen as an adjunct to antidepressant treatment. Journal of Clinical Psychiatry, 59 (suppl. 4), 15-24. 2. Hay, A. G., Bancroft, J., & Johnstone, E. C. (1994). Affective symptoms in women attending a menopause clinic. British Journal of Psychiatry, 164, 513-516. 3. Baker, A., Simpson, S., & Dawson, D. (1996). Sleep disruption and mood changes associated with menopause. Journal of Psychosomatic Research, 43, 359-369. 4. Busch, C. M., Zonderman, A. B., & Costa, P. T. (1994). Menopausal transition and psychological distress in a nationally representative sample: Is menopause associated with psychological distress? Journal of Aging and Health, 6, 209-228. 5. Avis, N. E., Brambilla, D., McKinlay, S. M., & Vass, K. (1994). A longitudinal analysis of the association between menopause and depression: Results from the Massachusett s Women s Health Study. Annals of Epidemiology, 4, 214-220. 6. Matthews, K. A. (1992). Myths and realities of the menopause. Psychosomatic Medicine, 54, 1-9. 7. Everson, S. A., Matthews, K. A., Guzick, D. S., Wing, R. R., & Kuller, L. H. (1995). Effects of surgical menopause on psychological characteristics and lipid levels: The Healthy Women Study. Health Psychology, 14, 435-443. 8. Zweifel, J. E., & O Brien, W. H. (1997). A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology, 22, 189-212. 9. Slaven, L., & Lee, C. (1997). Mood and symptom reporting among middle-aged women: The relationship between menopausal status, hormone replacement therapy, and exercise participation. Health Psychology, 16, 203-208. 10. Klaiber, E. L., Broverman, D. M., Vogel, W., Peterson, L. G., & Snyder, M. B. (1997). Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology, 22, 549-558. 11. Rousseau, M. E., & McCool, W. F. (1997). The menopausal experience of African American women: Overview and suggestions for research. Health Care for Women International, 18, 233-250. 12. Nabulsi, A. A., Folsom, A. R., White. A., Patsch. W., Heiss, G., Wu, K. K., & Szklo, M. (1993). Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The New England Journal of Medicine, 328, 1069-1075.